GLP-1 & Incretin Agonists

GLP-1 receptor agonists and the broader incretin / multi-incretin class are arguably the most consequential peptide drug development of the past two decades. The class began in 2005 with exenatide — a synthetic version of exendin-4, a peptide originally isolated from the venom of Heloderma suspectum (the Gila monster) by John Eng at the Bronx VA in 1992 — and has expanded through liraglutide, dulaglutide, semaglutide, the dual GLP-1/GIP agonist tirzepatide, and the triple GLP-1/GIP/glucagon agonist retatrutide. The pharmacology has steadily moved from once-twice-daily peptides through once-weekly agents to once-monthly and oral formulations, and the receptor scope has expanded from pure GLP-1 agonism through dual and triple receptor engagement. The clinical scope has expanded in parallel — from glycemic control in type 2 diabetes (the original indication) to obesity (semaglutide 2.4 mg STEP-1, 2021; tirzepatide SURMOUNT-1, 2022), cardiovascular outcomes in T2D (liraglutide LEADER 2016) and obesity without diabetes (semaglutide SELECT 2023), chronic kidney disease (semaglutide FLOW 2024), and metabolic dysfunction-associated steatohepatitis (semaglutide ESSENCE 2025). As of 2026 the class drives the largest pharmaceutical revenue lines in metabolic medicine, supports a substantial weight-loss telehealth industry, and faces intense competition from oral GLP-1 agonists (orforglipron, oral semaglutide), longer-acting injectables (maritide once-monthly), combination therapies (CagriSema, enicepatide+petrelintide), and adjacent classes including amylin analogs and selective glucagon agonists.

This page is the family-level pillar covering the GLP-1 / incretin agonist class as a whole. For individual drug pages with full evidence ratings, dosing, references, and trial-by-trial coverage, follow the links to each member peptide below. For the related amylin family (pramlintide, cagrilintide, petrelintide, eloralintide), see that family's pillar page.

Shared mechanism

GLP-1 receptor agonists activate the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed on pancreatic beta cells, alpha cells, hypothalamic appetite circuits, gastrointestinal smooth muscle, cardiomyocytes, vascular endothelium, kidney, and other tissues. GLP-1R activation drives multiple downstream effects: glucose-dependent insulin secretion (the safety-defining feature of the class — insulin release is enhanced only when blood glucose is elevated, minimizing hypoglycemia risk), glucagon suppression in pancreatic alpha cells, slowed gastric emptying (which contributes to postprandial glucose lowering and to early satiety perception underlying weight loss), central appetite suppression through hypothalamic and brainstem effects, and various cardiovascular, renal, and inflammatory effects that may underlie the class CV/kidney benefits.

The dual and triple agonists extend this profile. Tirzepatide adds GIP receptor (GIPR) co-agonism, with a roughly 9:1 GIP-over-GLP-1 receptor selectivity that produces additional insulinotropic effects through GIP and likely contributes to the larger weight loss observed compared with pure GLP-1 agonism. Retatrutide adds glucagon receptor (GCGR) agonism on top of GLP-1 and GIP agonism — counterintuitively for diabetes management, since glucagon raises glucose, but the integrated effect of all three receptors on hepatic glucose handling, energy expenditure, and lipid metabolism produces additional weight reduction. Survodutide adds glucagon to GLP-1 (no GIP). Mazdutide is a GLP-1/glucagon dual agonist developed in China. Enicepatide (CT-388, Roche) is a balanced GLP-1/GIP dual agonist with cAMP-biased signaling designed to address tirzepatide's tachyphylaxis liabilities.

Pharmacokinetic engineering has advanced in parallel. Native GLP-1 has a plasma half-life of approximately 2 minutes due to DPP-4 cleavage of the N-terminal His-Ala dipeptide. Therapeutic engineering has used (1) DPP-4-resistant analogs based on the Gly8 substitution, (2) C16 (liraglutide) or C18 (semaglutide) fatty-acid attachment for reversible albumin binding, (3) Fc-fusion (dulaglutide) or albumin-fusion (albiglutide) for FcRn-mediated half-life extension, and (4) more advanced fatty-acid plus spacer modifications for once-weekly (semaglutide, tirzepatide, dulaglutide), once-biweekly, or once-monthly (maritide) dosing intervals. Oral semaglutide uses the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) to overcome peptide oral bioavailability limits. Small-molecule GLP-1R agonists (orforglipron, danuglipron) bypass the peptide pharmacokinetic constraints entirely.

Clinical effects across the class share a common pattern: HbA1c reductions of 1-2 percent depending on agent and dose, body weight reductions of 4-25 percent depending on agent, dose, and duration, blood pressure reductions of 3-7 mmHg, and lipid improvements. The dominant adverse effect profile is gastrointestinal — nausea, vomiting, diarrhea, constipation — typically most prominent during dose escalation and improving with continued dosing. Cardiovascular outcomes data have been generally consistent across the class with MACE reductions in T2D populations with high CV risk; kidney and MASH outcomes are more recent and concentrated in the semaglutide trials with class-extrapolation discussions ongoing.

History & discovery

The incretin concept dates to the 1960s — Brown, Pederson, McIntosh, Dupré and others observed that orally administered glucose produced a substantially larger insulin response than equivalent intravenous glucose, implying that gut-derived signals (incretins) potentiate insulin secretion. GLP-1 itself was identified in the 1980s as a 30-residue peptide cleaved from preproglucagon by L-cells of the distal small intestine and colon, with active forms GLP-1(7-37) and GLP-1(7-36)-amide.

The pharmaceutical translation began with John Eng's 1992 isolation of exendin-4 from the venom of Heloderma suspectum (the Gila monster), reported in the Journal of Biological Chemistry. Exendin-4 was structurally related to GLP-1 but resistant to dipeptidyl peptidase-4 (DPP-4) — the enzyme that rapidly degrades native GLP-1 in plasma — giving it a far longer half-life suitable for therapeutic dosing. Goke and colleagues (J Biol Chem 1993) confirmed that exendin-4 is a high-potency agonist at the GLP-1 receptor on insulin-secreting beta cells, and that exendin-(9-39) is a useful antagonist for receptor pharmacology. Synthetic exendin-4 became exenatide, approved by the FDA in 2005 as Byetta (twice daily) — the first GLP-1 receptor agonist on the market and the founding member of the class.

The second-generation members emerged through the 2010s. Liraglutide (Victoza, Novo Nordisk, 2010) used C16 fatty-acid attachment for albumin binding and once-daily dosing, and was the first GLP-1 agonist with a dedicated cardiovascular outcomes trial: the 2016 LEADER trial (Marso et al., NEJM) showed a 13 percent reduction in major adverse cardiovascular events in T2D patients with high CV risk. Liraglutide 3.0 mg was approved as Saxenda for obesity in 2014. Dulaglutide (Trulicity, Eli Lilly, 2014) introduced the once-weekly Fc-fusion design. Albiglutide (Tanzeum/Eperzan, GSK, 2014) took the albumin-fusion route but was commercially discontinued in 2017-2018. Lixisenatide (Adlyxin, Sanofi, 2013) was a short-acting daily option.

The third generation — semaglutide and the dual/triple agonists — defined the modern era. Semaglutide (Ozempic for T2D, 2017; Rybelsus oral T2D, 2019; Wegovy for obesity, 2021) used C18 fatty-acid attachment with additional structural modifications producing a one-week half-life and substantially higher receptor occupancy than prior agents. The 2021 STEP-1 trial (Wilding et al., NEJM) demonstrated approximately 15 percent body weight reduction at 68 weeks in adults with overweight or obesity without diabetes — a tier of efficacy not previously reached in pharmacological weight loss. The 2023 SELECT trial (Lincoff et al., NEJM) extended the cardiovascular benefit to obesity without diabetes, and the 2024 FLOW trial (Perkovic et al., NEJM) demonstrated kidney outcomes benefit in T2D with chronic kidney disease, and the 2025 ESSENCE phase 3 trial (Sanyal et al., NEJM) showed efficacy in MASH. Tirzepatide (Mounjaro for T2D, 2022; Zepbound for obesity, 2023, Eli Lilly) added GIP receptor co-agonism to the GLP-1 backbone, with the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showing approximately 22 percent body weight reduction at the 15 mg dose. Retatrutide (Eli Lilly) added glucagon receptor agonism to GLP-1 and GIP, with the 2023 phase 2 trial (Jastreboff et al., NEJM 2023) showing approximately 24 percent body weight reduction at 48 weeks at the 12 mg dose.

The contemporary landscape (2026) is increasingly varied. Oral small-molecule GLP-1 agonists (orforglipron, Eli Lilly) are advancing through Phase 3, with patient-friendly oral dosing competing against injectable formulations. Long-acting injectables (maritide, Amgen, once-monthly subcutaneous; survodutide, Boehringer Ingelheim/Zealand, weekly GLP-1/glucagon dual agonist) extend dosing intervals or add receptor scope. Multi-agent combinations (CagriSema = cagrilintide + semaglutide; enicepatide/CT-388 + petrelintide) explore additive mechanisms. Chinese-developed agents (mazdutide GLP-1/glucagon dual agonist, ecnoglutide once-weekly GLP-1, ribupatide multi-agonist) reflect the global expansion of the class. The discontinued (albiglutide) and superseded (older once-weekly exenatide formulations) entries provide useful comparators. Amylin analogs (pramlintide, cagrilintide, petrelintide, eloralintide) sit in an adjacent peptide family and are increasingly co-administered with GLP-1 agonists.

State of evidence

Evidence in this class is among the strongest in any peptide drug category. Multiple randomized controlled trials at the tens-of-thousands-of-patients scale have established efficacy in glycemic control (every member through Phase 3 trials in T2D), body weight (STEP, SURMOUNT, SURPASS, SUSTAIN, AWARD, TIDE, EXCEL programs and others), and outcomes — cardiovascular (LEADER for liraglutide, SUSTAIN-6 for semaglutide, REWIND for dulaglutide, HARMONY OUTCOMES for albiglutide, ELIXA for lixisenatide, EXSCEL for exenatide, SELECT for semaglutide in obesity without diabetes, SOUL for oral semaglutide), kidney (FLOW for semaglutide), and MASH (ESSENCE for semaglutide).

The class is well-characterized for safety. The principal known concerns are: GI side effects (nausea, vomiting, diarrhea — usually dose-titration-related), pancreatitis class signal (modest but real, requires caution in patients with history of pancreatitis), gallbladder disease (gallstones and cholecystitis at modestly elevated rates), thyroid C-cell tumor risk (originating from rodent carcinogenicity studies — included as a boxed warning for the class but human relevance is unclear), and acute injury with severe nausea. Hypoglycemia is rare with monotherapy because of the glucose-dependent insulin secretion mechanism, but is meaningfully increased when combined with insulin or sulfonylureas — requiring downward titration of those agents.

For patients, the practical takeaway is that the GLP-1 / incretin class is the dominant pharmacological category for type 2 diabetes management (alongside SGLT2 inhibitors and metformin), the dominant pharmacological category for obesity (with bariatric surgery the alternative for severe obesity), and the emerging frontier for cardiovascular, kidney, and metabolic-liver protection. The choice between agents within the class depends on indication priority, dosing preference (daily vs weekly vs monthly vs oral), payer formulary, prior trial experience, and tolerance to GI side effects.

How members compare

Within the class, the principal comparison axes are receptor scope (pure GLP-1 vs GLP-1/GIP dual vs GLP-1/GIP/GCG triple), dosing interval (daily vs weekly vs monthly vs oral), and indication breadth (diabetes-only vs obesity-approved vs CV/kidney/MASH outcomes). For obesity, the cross-trial efficacy ranking at standard doses runs roughly: retatrutide (~24%) > tirzepatide (~22%) > semaglutide 2.4 mg (~15%) > liraglutide 3.0 mg (~8%) > older agents. For type 2 diabetes glycemic control the differences narrow but the same hierarchy generally holds. Modern guideline algorithms (ADA, EASD) increasingly favor GLP-1 receptor agonists alongside SGLT2 inhibitors as first-line additions to metformin in T2D, particularly in patients with established CV disease, CKD, or obesity.

Outside the GLP-1 class, the closest related peptide families are amylin analogs (pramlintide, cagrilintide, petrelintide, eloralintide — increasingly co-administered with GLP-1 agonists; CagriSema is the most-studied combination), oxyntomodulin (the dual GLP-1/glucagon natural peptide that established the rationale for survodutide and retatrutide's glucagon component), and GLP-2 / teduglutide (GLP-2 receptor agonism for short bowel syndrome — adjacent receptor, very different indication). Recombinant human insulin remains the irreplaceable foundation of T1D care and advanced T2D care; modern algorithms increasingly defer insulin escalation in favor of GLP-1-based therapy because of weight gain and hypoglycemia profiles.

Frequently asked questions

References

• Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreasOriginal Research

  Eng J, Kleinman WA, Singh L, Singh G, and Raufman JP, Journal of Biological Chemistry 1992. The discovery paper isolating exendin-4 from the venom of the Gila monster (Heloderma suspectum) and characterizing its receptor pharmacology — the molecule that became exenatide and founded the GLP-1 receptor agonist drug class.

• Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cellsOriginal Research

  Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, and Goke B, Journal of Biological Chemistry 1993. Established that exendin-4 is a high-potency GLP-1 receptor agonist on pancreatic beta cells, and that exendin-(9-39) is a useful antagonist for receptor pharmacology — the foundational receptor characterization for the class.

• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesReview

  Drucker DJ and Nauck MA, Lancet 2006. The standard early-era review framing the incretin pharmacology that underlies the GLP-1 receptor agonist class and DPP-4 inhibitor class. Daniel Drucker and Michael Nauck are the field's foundational figures.

• Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesClinical Trial

  Marso SP and colleagues, New England Journal of Medicine 2016. The LEADER trial — the first cardiovascular outcomes trial to show benefit for a GLP-1 receptor agonist (liraglutide) in T2D with high CV risk, demonstrating a 13% reduction in major adverse cardiovascular events. Established the class CV benefit framework.

• Once-Weekly Semaglutide in Adults with Overweight or ObesityClinical Trial

  Wilding JPH and colleagues, New England Journal of Medicine 2021. The STEP-1 trial — semaglutide 2.4 mg weekly in adults with overweight or obesity without diabetes, demonstrating approximately 15 percent body weight reduction at 68 weeks. Defined the modern obesity-pharmacotherapy era.

• Tirzepatide Once Weekly for the Treatment of ObesityClinical Trial

  Jastreboff AM and colleagues, New England Journal of Medicine 2022. The SURMOUNT-1 trial — tirzepatide (the dual GLP-1/GIP agonist) showing approximately 22 percent body weight reduction at the 15 mg dose in adults with obesity without diabetes. Extended the class efficacy ceiling and validated dual GLP-1/GIP agonism as a clinical strategy.

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialClinical Trial

  Jastreboff AM and colleagues, New England Journal of Medicine 2023. The retatrutide Phase 2 trial — the triple GLP-1/GIP/glucagon agonist showing approximately 24 percent body weight reduction at 48 weeks at the 12 mg dose. The strongest weight-loss signal for any pharmacological agent reported through 2023.

• Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesClinical Trial

  Lincoff AM and colleagues, New England Journal of Medicine 2023. The SELECT trial — semaglutide 2.4 mg in patients with overweight/obesity and established CV disease but without diabetes, demonstrating a 20% reduction in major adverse CV events. Extended the class CV benefit beyond T2D to the obesity population.

• Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesClinical Trial

  Perkovic V and colleagues, New England Journal of Medicine 2024. The FLOW trial — semaglutide in T2D with chronic kidney disease, demonstrating a 24% reduction in major kidney disease events. Established the kidney-outcomes benefit of the class in the T2D-CKD population.

• Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated SteatohepatitisClinical Trial

  Sanyal AJ and colleagues, New England Journal of Medicine 2025. The ESSENCE Phase 3 trial — semaglutide 2.4 mg in patients with biopsy-confirmed MASH, demonstrating efficacy on histological endpoints. Extended the GLP-1 class to liver outcomes.

Related goals